Last reviewed · How we verify
NCT04375280: EVALMOB
Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort
NA trial testing Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness. in Joint Osteoarthritis in 5,000 participants. Currently enrolling.
26 August 2035
Quick facts
| Lead sponsor | University Hospital, Clermont-Ferrand |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 5,000 |
| Start date | 27 August 2020 |
| Primary completion | 26 August 2035 |
| Estimated completion | 26 August 2035 |
| Sites | 1 location across France |
Drugs / interventions tested
- Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness.
Conditions studied
- Joint Osteoarthritis — all drugs for Joint Osteoarthritis →
- Atherosclerosis of the Distal Arteries, Without Gangrene — all drugs for Atherosclerosis of the Distal Arteries, Without Gangrene →
- Parkinson Disease — all drugs for Parkinson Disease →
- Chronic Obstructive Pulmonary Disease, Unspecified — all drugs for Chronic Obstructive Pulmonary Disease, Unspecified →
Sponsor
University Hospital, Clermont-Ferrand
Who can join
Adults 18 to 90, any sex, with Joint Osteoarthritis or Atherosclerosis of the Distal Arteries, Without Gangrene. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern. Therefore, the exploration of locomotor deficiencies, physical capacities and metabolism of patients with chronic illnesses constitutes a major challenge both for the treatment of causal pathologies, as well as for evaluating the impact of therapeutic interventions, the benefit of which will be an improvement in physical capacities and ultimately mobility. In view of the hypothesis of an increase in the prevalence of mobility disorders in this population, this approach is part of a logic of screening and improving the effectiveness of the care of these patients with a multidisciplinary evaluation of individual risks. The EVALMOB protocol was designed in order to try to determine a standard profile of "dysmobility" in patients with chronic illness
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Abnormality in field physical test predicts a reduced quadriceps strength in patients with hip- or knee-osteoarthritis. A prospective observational study.
Fanget Q, Verdilos A, Adelou S, Reynaud V, et al · · 2024 · PMID 39729442 · DOI 10.1371/journal.pone.0314524
Verify or expand the search:
- PubMed search for NCT04375280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Clermont-Ferrand trials
Trials by the same sponsor.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
- NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
- NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
- NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04375280 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
- Last refreshed: 28 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04375280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing